RETA
Retatrutide
A synthetic 39-amino-acid peptide built on a GIP-like backbone and carrying a fatty diacid on a lysine side chain. It is an agonist at three receptors rather than one or two: the GIP receptor, the GLP-1 receptor and the glucagon receptor. That third activity is the structural difference between it and the dual GIP/GLP-1 agonists listed elsewhere in this market.
Retatrutide has 20 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 26,015 planned or enrolled participants across the 19 studies that published a figure. No FDA-approved product contains Retatrutide. 157 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Retatrutide; the registry search is fuzzy, so every match is re-checked. None of this says whether Retatrutide works or is safe.
FDA status
Research only
Human studies
20
Furthest phase
Phase 3
Papers, 10 yr
157
Readership
49,387
monthly average, Feb–Jun 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
20
Registered human studies
Phase 3
Furthest phase reached
26,015
Planned or enrolled participants, across 19 studies that published a figure
None
No FDA-approved product contains it
33 loose registry matches were checked and 20 confirmed — 13 named something else and were discarded. We count a study only when Retatrutide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Retatrutide is, and what it has been studied for
Retatrutide is classified by ChEMBL as a protein, and appears in trial registrations under LY-3437943 and LY3437943. Its FDA substance identifier is NOP2Y096GV.
Across 20 registered trials, it has been studied in Obesity, Overweight, Type 2 Diabetes and Obstructive Sleep Apnea. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Hudson Biotech. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Retatrutide reached Phase 3 across 20 registered trials.
No FDA-approved product contains Retatrutide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Retatrutide?
Papers published each year that name Retatrutide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 16 | 5 | Yes |
| 2024 | 45 | 5 | Yes |
| 2025 | 58 | 7 | Yes |
| 2026 | 51 | 2 | No |
157 papers and 19 registered trials between 2017 and 2026. A paper counts when “Retatrutide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Retatrutide
157 indexed papers name Retatrutide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
- Retatrutide-A Game Changer in Obesity Pharmacotherapy
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
- The power of three: Retatrutide's role in modern obesity and diabetes therapy
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Collected 2026-08-02from PubMed, phrase-matched on “Retatrutide” in title and abstract. Run the same search.
About Retatrutide
A synthetic 39-amino-acid peptide built on a GIP-like backbone and carrying a fatty diacid on a lysine side chain. It is an agonist at three receptors rather than one or two: the GIP receptor, the GLP-1 receptor and the glucagon receptor. That third activity is the structural difference between it and the dual GIP/GLP-1 agonists listed elsewhere in this market.
- Also known as
- LY3437943
- Source
- ebi.ac.uk ↗
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.